Treatment of fibrotic interstitial lung disease: current approaches and future directions

Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that are often progressive and associated with high morbidity and early mortality. Important advancements in the past 10 years have enabled a better understanding, characterisation, and treatment of these diseases. This Series paper summarises the current approach to treatment of fibrotic ILDs, both pharmacological and non-pharmacological, including recent discoveries and practice-changing clinical trials. We further outline controversies and challenges, with discussion of evolving concepts and future research directions.

Automated summary

Fibrotic interstitial lung disease is a group of pulmonary disorders that are often progressive and associated with high morbidity and early mortality. Recent advancements have led to a better understanding and treatment of these diseases. Controversies and challenges exist, with evolving concepts being discussed as future research directions.